Trial Profile
A Prospective, Multicenter Non-interventional Study To Evaluate The Efficacy Of Enbrel (Registered) (Etanercept) Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis With Particular Focus On The Clinical Status Improvements Still Observable After 12 Weeks Of Treatment
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ADEQUATE
- Sponsors Pfizer
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 12 Dec 2017 Planned End Date changed from 30 Nov 2017 to 21 Dec 2017.
- 12 Dec 2017 Planned primary completion date changed from 30 Nov 2017 to 21 Dec 2017.